These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 19680167

  • 1. Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone.
    Ogata S, Ogihara Y, Nomoto K, Akiyama K, Nakahata Y, Sato K, Minoura K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2009 Nov; 66(5):577-84. PubMed ID: 19680167
    [Abstract] [Full Text] [Related]

  • 2. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 3. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
    Pediatrics; 2012 Jan; 129(1):e17-23. PubMed ID: 22144699
    [Abstract] [Full Text] [Related]

  • 4. [Steroid pulse therapy].
    Miura M.
    Nihon Rinsho; 2014 Sep; 72(9):1631-5. PubMed ID: 25518414
    [Abstract] [Full Text] [Related]

  • 5. [Methylprednisolone pulse therapy in Kawasaki disease].
    Miura M, Matsuoka M, Kohno K, Ohki H, Yoshiba S.
    Nihon Rinsho; 2008 Feb; 66(2):338-42. PubMed ID: 18265457
    [Abstract] [Full Text] [Related]

  • 6. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 7. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
    Fury W, Tremoulet AH, Watson VE, Best BM, Shimizu C, Hamilton J, Kanegaye JT, Wei Y, Kao C, Mellis S, Lin C, Burns JC.
    Hum Immunol; 2010 Sep 17; 71(9):865-73. PubMed ID: 20600450
    [Abstract] [Full Text] [Related]

  • 8. Response of refractory Kawasaki disease to intravenous methylprednisolone.
    Shah I, Prabhu SS.
    Ann Trop Paediatr; 2009 Mar 17; 29(1):51-3. PubMed ID: 19222935
    [Abstract] [Full Text] [Related]

  • 9. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin.
    Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M.
    Eur J Pediatr; 2008 Oct 17; 167(10):1119-23. PubMed ID: 18175148
    [Abstract] [Full Text] [Related]

  • 10. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
    Pediatr Int; 2001 Jun 17; 43(3):211-7. PubMed ID: 11380911
    [Abstract] [Full Text] [Related]

  • 11. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E.
    Am J Ther; 2016 Jun 17; 23(6):e1293-e1299. PubMed ID: 25611359
    [Abstract] [Full Text] [Related]

  • 12. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 17; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2014 Sep 17; 76(3):287-93. PubMed ID: 24964229
    [Abstract] [Full Text] [Related]

  • 14. Verification of risk scores to predict i.v. immunoglobulin resistance in incomplete Kawasaki disease.
    Kanamitsu K, Kakimoto H, Shimada A, Nakata Y, Ochi H, Watanabe H, Iwasaki Y, Tokorodani C, Kanazawa A, Maruyama H, Miyazawa M, Nishiuchi R, Kikkawa K.
    Pediatr Int; 2016 Feb 17; 58(2):146-51. PubMed ID: 26190225
    [Abstract] [Full Text] [Related]

  • 15. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H.
    J Pediatr; 2013 Aug 27; 163(2):521-6. PubMed ID: 23485027
    [Abstract] [Full Text] [Related]

  • 17. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S, Dong Y, Yin Y, Krucoff MW.
    Heart; 2013 Jan 27; 99(2):76-82. PubMed ID: 22869678
    [Abstract] [Full Text] [Related]

  • 18. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease.
    Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F, Okabe M, Cabral DA, Foell D, Brown KL, Kessel C.
    Arthritis Rheumatol; 2019 May 27; 71(5):792-804. PubMed ID: 30447136
    [Abstract] [Full Text] [Related]

  • 19. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
    Inoue T, Murakami S, Matsumoto K, Matsuda A.
    Pediatr Rheumatol Online J; 2020 Oct 06; 18(1):76. PubMed ID: 33023630
    [Abstract] [Full Text] [Related]

  • 20. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 06; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.